Nauck MA - Search Results

1

Unraveling the science of incretin biology.

Nauck MA. Nauck MA. Am J Med. 2009 Jun;122(6 Suppl):S3-S10. doi: 10.1016/j.amjmed.2009.03.012. Am J Med. 2009. PMID: 19464426 Review.

2

Effects of single and combined infusions of human biosynthetic proinsulin and insulin on glucose metabolism and on plasma hormone concentrations in euglycaemic clamp experiments.

Nauck MA, Stöckmann F, Thiery J, Ebert R, Creutzfeldt W. Nauck MA, et al. Horm Metab Res Suppl. 1988;18:60-7. Horm Metab Res Suppl. 1988. PMID: 3056814

3

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.

Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Nauck M, et al. Diabetologia. 1986 Jan;29(1):46-52. doi: 10.1007/BF02427280. Diabetologia. 1986. PMID: 3514343

4

Preserved incretin effect after complete surgical denervation of the pancreas in young pigs.

Nauck M, van Hoorn W, Gubernatis G, Ebert R, Siewert JR, Creutzfeldt W. Nauck M, et al. Res Exp Med (Berl). 1985;185(4):291-8. doi: 10.1007/BF01851954. Res Exp Med (Berl). 1985. PMID: 3901165

5

Preserved incretin effect in type 1 diabetic patients with end-stage nephropathy treated by combined heterotopic pancreas and kidney transplantation.

Nauck MA, Büsing M, Orskov C, Siegel EG, Talartschik J, Baartz A, Baartz T, Hopt UT, Becker HD, Creutzfeldt W. Nauck MA, et al. Acta Diabetol. 1993;30(1):39-45. doi: 10.1007/BF00572873. Acta Diabetol. 1993. PMID: 8329730

6

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W. Nauck MA, et al. Diabetologia. 1993 Aug;36(8):741-4. doi: 10.1007/BF00401145. Diabetologia. 1993. PMID: 8405741 Clinical Trial.

7

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.

Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Nauck MA, et al. J Clin Invest. 1993 Jan;91(1):301-7. doi: 10.1172/JCI116186. J Clin Invest. 1993. PMID: 8423228 Free PMC article. Clinical Trial.

8

Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations.

Nauck MA, Bartels E, Orskov C, Ebert R, Creutzfeldt W. Nauck MA, et al. J Clin Endocrinol Metab. 1993 Apr;76(4):912-7. doi: 10.1210/jcem.76.4.8473405. J Clin Endocrinol Metab. 1993. PMID: 8473405 Clinical Trial.

9

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

Willms B, Werner J, Holst JJ, Orskov C, Creutzfeldt W, Nauck MA. Willms B, et al. Among authors: nauck ma. J Clin Endocrinol Metab. 1996 Jan;81(1):327-32. doi: 10.1210/jcem.81.1.8550773. J Clin Endocrinol Metab. 1996. PMID: 8550773 Clinical Trial.

10

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Creutzfeldt WO, et al. Among authors: nauck ma. Diabetes Care. 1996 Jun;19(6):580-6. doi: 10.2337/diacare.19.6.580. Diabetes Care. 1996. PMID: 8725855 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results